Infliximab is a chimeric monoclonal antibody to tumor necrosis factor-α that has been demonstrated to heal as many as 50% of chronic intestinal fistulas in patients with Crohn's disease.11In patients who show no response to the conservative treatment of fistulas after a period of 6 to 12 weeks, surgical treatment should be selected, as spontaneous closure is subsequently unlikely.2In patients who exhibit malignancy or the presence of a foreign body, as well as distal obstruction, early intervention is indicated, even in those with low-output fistulas.2 Here, TNF is linked to Crohn disease.